ArticleJournal of pharmaceutical policy and practice2026
The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Regulatory agencies ensure the safety, efficacy, and quality of pharmaceuticals, influencing patient access to novel therapies. The Saudi Food and Drug Authority (SFDA) oversees drug evaluation in Saudi Arabia. This study evaluates SFDA's drug review times compared to other international agencies and assesses characteristics and approval timelines of novel drugs approved by the SFDA and the U.S. Food and Drug Administration (FDA) in 2019. Methods: A retrospective observational study analyzed drug evaluation times from the SFDA and six international agencies: FDA, European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), and Swissmedic. The primary outcome was drug approval timeline, defined as days from submission to registration. Data on 48 novel drugs approved by the FDA in 2019 were collected and tracked for SFDA approval status through 2024. Descriptive statistics compared drug characteristics and evaluation times. A regulatory comparison used publicly available documents and reported timelines. Results: SFDA and EMA showed shorter median approval times (∼6.5 months), while Swissmedic (14.5 months) and PMDA (10.6 months) had longer timelines. Among 48 FDA-approved novel drugs in 2019, 21 (43.75%) were approved by the SFDA by mid-2024; 23 (47.92%) were not submitted for SFDA review, impacting coverage. Small molecules dominated approvals for both FDA (58.33%) and SFDA (64%). Advanced therapies such as gene therapies and synthetic peptide analogs were absent from SFDA approvals, mainly due to non-submission. Median approval times were comparable (SFDA: 248 days; FDA: 243 days), with greater variability observed in SFDA timelines. Conclusion: SFDA's review timelines align with major regulatory agencies, supporting timely drug access. Further investigation into submission patterns and regulatory challenges may improve approval rates, especially for advanced therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.